Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript

John Coleman

Will now come to order. My name is John Coleman. I am the Lead Independent Director of the Board of Kane Biotech. I would like to welcome all shareholders and guests to the 2026 Annual and Special Meeting of the Shareholders of Kane Biotech, Inc.

I will act as Chair of the meeting, and Ray Dupuis will act as Secretary of the meeting. Ms. Kristine Calesso, and Ms. [ Natalie Sanchez-Jamenez ] of TSX Trust Company are acting as scrutineers for this meeting.

The notice calling this meeting was mailed to all shareholders of record on May 8, 2026, in accordance with the corporation’s bylaws and applicable securities laws. Will the scrutineer please submit the report on shareholder attendance and proxies received? I believe you might be muted.

Ray Dupuis
Chief Financial Officer

That’s — John, you read out the scrutineer.

John Coleman

Sorry, I just read it. Sorry. I thought the scrutineer was reading that. My apologies. Scrutineer’s report is as follows: the number of shareholders present in person or by proxy is 33. The number of shares represented is 83,622,028, representing approximately 45.98% of the corporation’s issued and outstanding common shares entitled to vote at this meeting.

I hereby adopt the scrutineer’s report. Notice having been duly given and quorum being present in accordance with the corporation’s bylaws and the Canadian Business Corporations Act, I hereby declare this meeting duly constituted for the transaction of business.

The next item of business is the presentation of the corporation’s audited financial statements for the fiscal year ended December 31, 2025, together with the independent auditor’s